These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37894366)

  • 21. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
    Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok TSK; Yang JC; Hoyle C
    Clin Drug Investig; 2018 Apr; 38(4):319-331. PubMed ID: 29247383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience.
    Makarov M; Peled N; Shochat T; Zer A; Rotem O; Dudnik E
    Isr Med Assoc J; 2019 Jun; 21(6):394-398. PubMed ID: 31280508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.
    Poh ME; Balakrishnan S; Tan SN; Zainal Abidin MA; Liam CK; Tan JL; Pang YK; Alaga A; Tho LM; How SH
    Transl Lung Cancer Res; 2024 Jul; 13(7):1649-1659. PubMed ID: 39118879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
    Yi XF; Song J; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Ma JT; Han CB
    Front Oncol; 2022; 12():863666. PubMed ID: 35785185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.
    Buder A; Hochmair MJ; Filipits M
    Target Oncol; 2021 Jan; 16(1):77-84. PubMed ID: 33270169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
    Kiura K; Yoh K; Katakami N; Nogami N; Kasahara K; Takahashi T; Okamoto I; Cantarini M; Hodge R; Uchida H
    Cancer Sci; 2018 Apr; 109(4):1177-1184. PubMed ID: 29363250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
    Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
    Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.
    Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
    Thorac Cancer; 2022 Jul; 13(13):1888-1897. PubMed ID: 35633141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
    Tsubata Y; Watanabe K; Saito R; Nakamura A; Yoshioka H; Morita M; Honda R; Kanaji N; Ohizumi S; Jingu D; Nakagawa T; Nakazawa K; Mouri A; Takeuchi S; Furuya N; Akazawa Y; Miura K; Ichihara E; Maemondo M; Morita S; Kobayashi K; Isobe T
    Int J Clin Oncol; 2022 Jan; 27(1):112-120. PubMed ID: 34643820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
    Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
    O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
    Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
    Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W
    Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
    Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
    Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
    Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Tamiya N; Goto Y; Kanda H; Chihara Y; Kunimatsu Y; Katayama Y; Iwasaku M; Tokuda S; Takayama K
    Target Oncol; 2023 Sep; 18(5):657-665. PubMed ID: 37610516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
    Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
    Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
    Bollinger MK; Agnew AS; Mascara GP
    J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.